Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cephalon, Inc.

http://www.cephalon.com

Latest From Cephalon, Inc.

BMS ‘Increasingly Confident’ It Can Handle The Impact Of Medicare Pricing For Eliquis

Bristol’s CEO offered assurances about Medicare negotiations under the IRA as the company delivered better-than-expected second quarter results across new and legacy products.

Medicare Launches

Examining The Antibody-Drug Conjugate Pipeline

An analysis of new ADCs in Phase III studies shows the difficulties, and possible rewards, of developing these drugs. The earlier stage pipeline boasts a range of mechanistic approaches. 

Clinical Trials Growth

Digital Health Roundup: Brain Talk On Seizures, Alzheimer's, Stress, Anxiety; Medtronic's OR Report; Health Care AI; UK Guidances

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights AI discussions at the HLTH Europe conference and an interview with Motif Neurotech's CEO Jacob Robinson. Elizabeth Orr discusses DeepWell DTx's newly launched VR game for treating stress-related hypertension and anxiety. Natasha Barrow provides an overview of Digital Mental Health Technologies regulation in the UK and Brian Bossetta reports ‘the good and bad’ from Medtronic's report on digital technologies' use in the operating room. 

Digital Health Roundup Digital Health

Stock Watch: Investor Reactions Diverge As J&J And Novartis Report Q2 Results

Both of the first two companies to report second-quarter financials maintained full-year sales guidance. But while Johnson & Johnson’s investors seemed cheered, Novartis’s may have been concerned about familiar issues.

Stock Watch Sales & Earnings
See All

Company Information

  • Other Names / Subsidiaries
    • Arana Therapeutics (Peptech and EvoGenix)
    • BioAssets Development Corporation
    • Ception Therapeutics
    • ChemGenex Pharmaceuticals Limited
    • CIMA Labs
    • Gemin X Pharmaceuticals
    • Zeneus Pharma
    • Mepha
UsernamePublicRestriction

Register